Enrique Poradosu
Gründer bei NUVECTIS PHARMA, INC.
Vermögen: 10 Mio $ am 31.05.2024
Aktive Positionen von Enrique Poradosu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
NUVECTIS PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 27.07.2020 | - |
Gründer | 27.07.2020 | - |
Karriereverlauf von Enrique Poradosu
Ehemalige bekannte Positionen von Enrique Poradosu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2016 | 01.12.2020 |
KERYX BIOPHARMACEUTICALS | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2003 | 01.01.2016 |
Ausbildung von Enrique Poradosu
The Hebrew University of Jerusalem | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Israel | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
NUVECTIS PHARMA, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Börse
- Insiders
- Enrique Poradosu
- Erfahrung